Medical marijuana does not negatively impact long-term brain function in older adults according to new study.
Using medicinal marijuana does not lead to long-term negative implications on brain function according to Israeli researchers.
A new study published in the journal Drug and Alcohol Review, concluded that there was no difference in brain health between cannabis users and non-users in older adults. The study was performed by researchers at the University of Haifa and the Technion-Israel Institute of Tech last month.
Researchers gathered 125 chronic pain patients over the age of 50. Patients were tested on their cognitive performances: specifically, new learning, working memory, and reaction times. Overall, there was no difference in brain function between cannabis users and non-users.
Furthermore, no significant difference was found between cannabis users. In fact, brain health was not affected regardless of dosage, frequency, years of use, and THC/CBD concentration. There was also no difference in function in relation to whether cannabis was acquired legally or illegally.
In conclusion, researchers state that while medical marijuana has no long-term negative implications on brain function, there is still a demand for more research.
MC does not have a widespread impact on cognition in older chronic pain patients. . . Future studies are urgently needed to further clarify the implications of late-life cannabis use for brain health.Study co-authors – Drug and Alcohol Review
Research into medical marijuana has proven to have a plethora of health benefits, especially for chronic pain and muscles spasticity. Furthermore, according to previous studies, medical marijuana can also positively impact overall quality of life in those who use cannabis later in life.
Globally, the demand for access to medical marijuana is rising. In the midst of the U.S election next month, multiple state initiatives may make their way into the Constitution pending on citizen votes. In Australia, the Therapeutic Goods Association (TGA) has also de-scheduled CBD from a Schedule IV to a Schedule III drug. In turn, allowing patients to purchase CBD products over the counter.
According to researchers, the study can allow room to develop more of an understanding of its implications within mature demographics.
Get the Latest Marijuana News &
Content in your Inbox!
All your support helps The Green Fund keep writing content for all you
marijuana enthusiasts and potential pot stock investors